Blueprint Medicines Co. (NASDAQ:BPMC) CFO Sells $1,050,000.00 in Stock

Blueprint Medicines Co. (NASDAQ:BPMC) CFO Michael Landsittel sold 10,000 shares of the stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $105.00, for a total transaction of $1,050,000.00. Following the completion of the transaction, the chief financial officer now owns 47,286 shares of the company’s stock, valued at approximately $4,965,030. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Michael Landsittel also recently made the following trade(s):

• On Thursday, March 28th, Michael Landsittel sold 5,000 shares of Blueprint Medicines stock. The shares were sold at an average price of $95.00, for a total transaction of $475,000.00.
• On Friday, March 15th, Michael Landsittel sold 13,734 shares of Blueprint Medicines stock. The shares were sold at an average price of $87.78, for a total transaction of $1,205,570.52.
• On Thursday, March 7th, Michael Landsittel sold 5,003 shares of Blueprint Medicines stock. The shares were sold at an average price of $90.69, for a total transaction of $453,722.07.

Blueprint Medicines Stock Down 0.9 %

NASDAQ:BPMC traded down $0.94 during mid-day trading on Monday, reaching $106.25. The stock had a trading volume of 803,137 shares, compared to its average volume of 778,452. The business’s 50 day moving average is $91.77 and its 200 day moving average is $80.95. Blueprint Medicines Co. has a fifty-two week low of $43.89 and a fifty-two week high of $110.93. The stock has a market cap of $6.50 billion, a P/E ratio of -22.14 and a beta of 0.65. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.76 and a quick ratio of 3.61.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings results on Thursday, February 15th. The biotechnology company reported ($1.82) EPS for the quarter, beating the consensus estimate of ($2.04) by $0.22. Blueprint Medicines had a negative return on equity of 193.48% and a negative net margin of 102.15%. The company had revenue of $71.96 million for the quarter, compared to the consensus estimate of $67.34 million. During the same quarter last year, the company posted ($2.65) earnings per share. The company’s revenue for the quarter was up 85.5% compared to the same quarter last year. As a group, sell-side analysts predict that Blueprint Medicines Co. will post -5.38 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on BPMC shares. Needham & Company LLC reissued a “buy” rating and issued a $97.00 price target on shares of Blueprint Medicines in a report on Thursday. Piper Sandler upped their price target on shares of Blueprint Medicines from $78.00 to $104.00 and gave the company a “neutral” rating in a report on Friday. Citigroup upped their price target on shares of Blueprint Medicines from $65.00 to $76.00 and gave the company a “sell” rating in a report on Friday. The Goldman Sachs Group upped their price target on shares of Blueprint Medicines from $121.00 to $168.00 and gave the company a “buy” rating in a report on Monday. Finally, Barclays upped their price objective on shares of Blueprint Medicines from $70.00 to $75.00 and gave the company an “equal weight” rating in a research note on Friday. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $100.31.

Hedge Funds Weigh In On Blueprint Medicines

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Readystate Asset Management LP acquired a new stake in shares of Blueprint Medicines in the fourth quarter worth $3,692,000. American Century Companies Inc. lifted its position in Blueprint Medicines by 5.2% in the third quarter. American Century Companies Inc. now owns 670,972 shares of the biotechnology company’s stock worth $33,696,000 after purchasing an additional 33,243 shares during the period. Diversified Trust Co lifted its position in Blueprint Medicines by 2.9% in the third quarter. Diversified Trust Co now owns 11,219 shares of the biotechnology company’s stock worth $563,000 after purchasing an additional 318 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in Blueprint Medicines by 95.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,550 shares of the biotechnology company’s stock worth $78,000 after purchasing an additional 757 shares during the period. Finally, Rafferty Asset Management LLC lifted its position in Blueprint Medicines by 17.4% in the third quarter. Rafferty Asset Management LLC now owns 166,690 shares of the biotechnology company’s stock worth $8,371,000 after purchasing an additional 24,693 shares during the period.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.